Program
Anti-CEACAM5 Antibody-drug Conjugate IBI3020
Its studies are led by Innovent Biologics.
Furthest: phase 1, since Apr 30, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 11 open or running | phase 1since Apr 30, 2025 | Apr 30, 2025 | Dec 31, 2027phase 1 · NCT06963281 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2025First study: phase 1 study in Solid TumorsFirst studyNCT06963281 · 285 planned · United States, China
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Solid TumorsNCT06963281
TargetBeta
CEACAM5 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA) ”NCIt, by rule
Other programs on CEACAM5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| precemtabart tocentecanrule | Merck KGaA, Darmstadt, Germany | phase 3 | 4 |
| Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 | Sino Biopharmaceutical | phase 2 | 2 |
| Anti-CEACAM5 Antibody-drug Conjugate BMS-986490rule | Bristol-Myers Squibb | phase 2 | 1 |
| tusamitamab sonditecan | Pfizer | phase 1 | 1 |
| RO7821657rule | Hoffmann-La Roche | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06963281Solid Tumors · United States, China | 1 | Recruiting | Dec 31, 2027 | 285 |
How it is read
Names in the registry
- “IBI3020”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.